Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats

Neuroscience Letters

Volumn 444, Issue 2, 2008, Pages 186-189

  Jenkins, Trisha A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Angiotensin; Angiotensin converting enzyme; Angiotensin converting enzyme inhibitor; Angiotensin receptor antagonist; Dopamine; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; DRINKING WATER; DRUG METABOLITE; HOMOVANILLIC ACID; NEUROTRANSMITTER; NORADRENALIN; PERINDOPRIL; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; EXPERIMENTAL RAT; FRONTAL CORTEX; HIPPOCAMPUS; LIMBIC SYSTEM; MALE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE SECTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BRAIN; DOPAMINE; MALE; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PERINDOPRIL; RATS; SEROTONIN; TETRAZOLES;

EID: 51349102439     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.08.021     Document Type: Article

References (54)

1. Allen A.M., Moeller I., Jenkins T.A., Zhuo J., Aldred G.P., Chai S.Y., and Mendelsohn F.A. Angiotensin receptors in the nervous system. Brain Res. Bull. 47 1 (1998) 17-28
2. Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am. J. Cardiovasc. Drugs 7 1 (2007) 17-24
3. Amenta F., Mignini F., Rabbia F., Tomassoni D., and Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J. Neurol. Sci. 203-204 (2002) 147-151
4. Boules M., Shaw A., Fredrickson P., and Richelson E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 21 1 (2007) 13-23
5. Brown D.C., Steward L.J., Ge J., and Barnes N.M. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br. J. Pharmacol. 118 2 (1996) 414-420
6. Brugts J.J., Boersma E., Chonchol M., Deckers J.W., Bertrand M., Remme W.J., Ferrari R., Fox K., and Simoons M.L. EUROPA Investigators, The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J. Am. Coll. Cardiol. 50 22 (2007) 2148-2155
7. Chai S.Y., Zhuo J., and Mendelsohn F.A. Localization of components of the renin-angiotensin system and site of action of inhibitors. Arzneimittelforschung 43 2A (1993) 214-221
8. Cheung B.M. Therapeutic potential of angiotensin receptor blockers in hypertension. Exp. Opin. Invest. Drugs 15 6 (2006) 625-635
9. Cools R., Roberts A.C., and Robbins T.W. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn. Sci. 12 1 (2008) 31-40
10. Cox S.L., Trendelenburg A.U., and Starke K. Prejunctional angiotensin receptors involved in the facilitation of noradrenaline release in mouse tissues. Br. J. Pharmacol. 127 5 (1999) 1256-1262
11. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33 4 (2002) 1152-1162
12. Dwoskin L.P., Jewell A.L., and Cassis L.A. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum. Naunyn Schmiedebergs Arch. Pharmacol. 345 2 (1992) 153-159
13. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Exp. Rev. Cardiovasc. Ther. 3 1 (2005) 15-29
14. Fink K.B., and Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol. Rev. 59 4 (2007) 360-417
15. Ganten D., Lang R.E., Lehmann E., and Unger T. Brain angiotens: on the way to becoming a well-studied neuropeptide system. Biochem. Pharmacol. 33 22 (1984) 3523-3528
16. Gard P.R. The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol. 438 1-2 (2002) 1-14
17. Gard P.R. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Exp. Opin. Ther. Targets 8 1 (2004) 7-14
18. Gard P.R., and Rusted J.M. Angiotensin and Alzheimer's disease: therapeutic prospects. Exp. Rev. Neurother. 4 1 (2004) 87-96
19. Gerstberger R., Muller A.R., and Simon-Oppermann C. Functional hypothalamic angiotensin II and catecholamine receptor systems inside and outside the blood-brain barrier. Prog. Brain Res. 91 (1992) 423-433
20. Grippo A.J., and Johnson A.K. Biological mechanisms in the relationship between depression and heart disease. Neurosci. Biobehav. Rev. 26 8 (2002) 941-962
21. Herpfer I., and Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19 4 (2005) 275-293
22. Hiramatsu M., and Kameyama T. Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models. Methods Find. Exp. Clin. Pharmacol. 20 7 (1998) 595-599
23. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural. Transm. 109 5-6 (2002) 813-836
24. Jenkins T.A., Chai S.Y., Howells D.W., and Mendelsohn F.A. Intrastriatal angiotensin II induces turning behaviour in 6-hydroxydopamine lesioned rats. Brain Res. 691 1-2 (1995) 213-216
25. Jenkins T.A., Chai S.Y., and Mendelsohn F.A. Upregulation of angiotensin II AT1 receptors in the mouse nucleus accumbens by chronic haloperidol treatment. Brain Res. 748 1-2 (1997) 137-142
26. Jenkins T.A., Mendelsohn F.A., and Chai S.Y. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J. Neurochem. 68 3 (1997) 1304-1311
27. Jenkins T.A., Wong J.Y., Howells D.W., Mendelsohn F.A., and Chai S.Y. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J. Neurochem. 73 1 (1999) 214-219
28. Kehoe P.G., and Wilcock G.K. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol. 6 4 (2007) 373-378
29. Kurosaki R., Muramatsu Y., Imai Y., Kato H., and Araki T. Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice. Neurol. Res. 26 6 (2004) 644-657
30. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., and Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J. Neurosci. Res. 81 6 (2005) 865-873
31. Loy R., Koziell D.A., Lindsey J.D., and Moore R.Y. Noradrenergic innervation of the adult rat hippocampal formation. J. Comp. Neurol. 189 4 (1980) 699-710
32. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., and Chai S.Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 35 6 (2003) 901-918
33. Mendelsohn F.A., Chai S.Y., and Dunbar M. In vitro autoradiographic localization of angiotensin-converting enzyme in rat brain using 125I-labelled MK351A. J. Hypertens. 2 Suppl. 3 (1984) S41-S44
34. Mendelsohn F.A., Jenkins T.A., and Berkovic S.F. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 613 2 (1993) 221-229
35. Meredith P.A. Candesartan cilexetil-a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr. Med. Res. Opin. 23 7 (2007) 1693-1705
36. Mullins J.J., Peters J., and Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344 6266 (1990) 541-544
37. Munoz A., Rey P., Guerra M.J., Mendez-Alvarez E., Soto-Otero R., and Labandeira-Garcia J.L. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51 1 (2006) 112-120
38. Obata T. Imidaprilat suppresses nonylphenol and 1-methyl-4-phenylpyridinium ion (MPP+)-induced hydroxyl radical generation in rat striatum. Neurosci. Res. 54 3 (2006) 192-196
39. Obata T. Imidaprilat an angiotensin-converting enzyme inhibitor exerts neuroprotective effect via decreasing dopamine efflux and hydroxyl radical generation induced by bisphenol A and MPP+ in rat striatum. Brain Res. 1071 1 (2006) 250-253
40. Plosker G.L., and McTavish D. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Drugs Aging 7 3 (1995) 226-253
41. Raghavendra V., Chopra K., and Kulkarni S.K. Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan. Neuropeptides 32 3 (1998) 275-280
42. Ripley T.L., Chonlahan J.S., and Germany R.E. Candesartan in heart failure. Clin. Interv. Aging 1 4 (2006) 357-366
43. Rodriguez-Campos M., Kadarian C., Rodano V., Bianciotti L., Fernandez B., and Vatta M. AT-1 receptor and phospholipase C are involved in angiotensin III modulation of hypothalamic noradrenergic transmission. Cell Mol. Neurobiol. 20 6 (2000) 747-762
44. Rogerson F.M., Schlawe I., Paxinos G., Chai S.Y., McKinley M.J., and Mendelsohn F.A. Localization of angiotensin converting enzyme by in vitro autoradiography in the rabbit brain. J. Chem. Neuroanat. 8 4 (1995) 227-243
45. Saavedra J.M. Brain and pituitary angiotensin. Endocr. Rev. 13 2 (1992) 329-380
46. Saavedra J.M. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol. Neurobiol. 25 3-4 (2005) 485-512
47. Sakaguchi K., Chai S.Y., Jackson B., Johnston C.I., and Mendelsohn F.A. Differential angiotensin-converting enzyme inhibition in brain after oral administration of perindopril demonstrated by quantitative in vitro autoradiography. Neuroendocrinology 48 3 (1988) 223-228
48. Sirvio J., and MacDonald E. Central alpha1-adrenoceptors: their role in the modulation of attention and memory formation. Pharmacol. Ther. 83 1 (1999) 49-65
49. Skidgel R.A., Defendini R., and Erdos E.G. Angiotensin I converting enzyme and its role in neuropeptide metabolism. In: Turner A.J. (Ed). Neuropeptides and their Peptidases (1987), Ellis Horwood Ltd., Chichester, UK p. 165
50. Skoog I., and Gustafson D. Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol. Res. 25 6 (2003) 675-680
51. Sumners C., and Phillips M.I. Central injection of angiotensin II alters catecholamine activity in rat brain. Am. J. Physiol. 244 2 (1983) R257-R263
52. Tanaka J., Miyakubo H., Kawakami A., Hayashi Y., and Nomura M. Involvement of NMDA receptor mechanisms in the modulation of serotonin release in the lateral parabrachial nucleus in the rat. Brain Res. Bull. 71 1-3 (2006) 311-315
53. Voigt J.P., Hortnagl H., Rex A., van Hove L., Bader M., and Fink H. Brain angiotensin and anxiety-related behavior: the transgenic rat TGR(ASrAOGEN)680. Brain Res. 1046 1-2 (2005) 145-156
54. Voigt J.P., Rex A., Sohr R., and Fink H. Hippocampal 5-HT and NE release in the transgenic rat TGR(mREN2)27 related to behavior on the elevated plus maze. Eur. Neuropsychopharmacol. 9 4 (1999) 279-285